# First In Human Study of CX-2051 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06265688/  
OnCo record `nct06265688` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Varsetatug masetecan run by CytomX Therapeutics, now recruiting.

## Summary

First In Human Study of CX-2051 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06265688 by CytomX Therapeutics, with 160 participants planned, started 2024-04-02. Conditions recorded: Solid Tumor, Adult. Interventions recorded: CX-2051 and Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06265688
- Phase: 1
- Setting: An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
- Sponsor: CytomX Therapeutics
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06265688: https://clinicaltrials.gov/study/NCT06265688

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Varsetatug masetecan](https://onco.cc/drugs/varsetatug-masetecan/)
- companies: [CytomX Therapeutics](https://onco.cc/companies/cytomx-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06265688.json